Berberine prevents NAFLD and HCC by modulating metabolic disorders

IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pharmacology & Therapeutics Pub Date : 2024-02-01 DOI:10.1016/j.pharmthera.2024.108593
Xinyue Lin , Juanhong Zhang , Yajun Chu , Qiuying Nie , Junmin Zhang
{"title":"Berberine prevents NAFLD and HCC by modulating metabolic disorders","authors":"Xinyue Lin ,&nbsp;Juanhong Zhang ,&nbsp;Yajun Chu ,&nbsp;Qiuying Nie ,&nbsp;Junmin Zhang","doi":"10.1016/j.pharmthera.2024.108593","DOIUrl":null,"url":null,"abstract":"<div><p>Non-alcoholic fatty liver disease (NAFLD) is a global metabolic disease<span><span> with high prevalence in both adults and children. Importantly, NAFLD is becoming the main cause of hepatocellular carcinoma (HCC). </span>Berberine (BBR), a naturally occurring plant component, has been demonstrated to have advantageous effects on a number of metabolic pathways as well as the ability to kill liver tumor cells by causing cell death and other routes. This permits us to speculate and make assumptions about the value of BBR in the prevention and defense against NAFLD and HCC by a global modulation of metabolic disorders. Herein, we briefly describe the etiology of NAFLD and NAFLD-related HCC, with a particular emphasis on analyzing the potential mechanisms of BBR in the treatment of NAFLD from aspects including increasing insulin sensitivity, controlling the intestinal milieu, and controlling lipid metabolism. We also elucidate the mechanism of BBR in the treatment of HCC. More significantly, we provided a list of clinical studies for BBR in NAFLD. Taking into account our conclusions and perspectives, we can make further progress in the treatment of BBR in NAFLD and NAFLD-related HCC.</span></p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"254 ","pages":"Article 108593"},"PeriodicalIF":12.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163725824000135","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a global metabolic disease with high prevalence in both adults and children. Importantly, NAFLD is becoming the main cause of hepatocellular carcinoma (HCC). Berberine (BBR), a naturally occurring plant component, has been demonstrated to have advantageous effects on a number of metabolic pathways as well as the ability to kill liver tumor cells by causing cell death and other routes. This permits us to speculate and make assumptions about the value of BBR in the prevention and defense against NAFLD and HCC by a global modulation of metabolic disorders. Herein, we briefly describe the etiology of NAFLD and NAFLD-related HCC, with a particular emphasis on analyzing the potential mechanisms of BBR in the treatment of NAFLD from aspects including increasing insulin sensitivity, controlling the intestinal milieu, and controlling lipid metabolism. We also elucidate the mechanism of BBR in the treatment of HCC. More significantly, we provided a list of clinical studies for BBR in NAFLD. Taking into account our conclusions and perspectives, we can make further progress in the treatment of BBR in NAFLD and NAFLD-related HCC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
小檗碱通过调节代谢紊乱预防非酒精性脂肪肝和肝癌
非酒精性脂肪肝(NAFLD)是一种全球性代谢疾病,在成人和儿童中发病率都很高。重要的是,非酒精性脂肪肝正成为肝细胞癌(HCC)的主要病因。小檗碱(BBR)是一种天然植物成分,已被证实对多种代谢途径具有有利影响,并能通过导致细胞死亡和其他途径杀死肝肿瘤细胞。因此,我们可以推测和假设 BBR 在通过全面调节代谢紊乱来预防和抵御非酒精性脂肪肝和 HCC 方面的价值。在此,我们简要介绍了非酒精性脂肪肝和非酒精性脂肪肝相关的 HCC 的病因,并着重从提高胰岛素敏感性、控制肠道环境和控制脂质代谢等方面分析了 BBR 治疗非酒精性脂肪肝的潜在机制。我们还阐明了 BBR 治疗 HCC 的机制。更重要的是,我们提供了非酒精性脂肪肝中 BBR 的临床研究清单。考虑到我们的结论和展望,我们可以在非酒精性脂肪肝和非酒精性脂肪肝相关 HCC 的 BBR 治疗方面取得进一步进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
23.00
自引率
0.70%
发文量
222
审稿时长
90 days
期刊介绍: Pharmacology & Therapeutics, in its 20th year, delivers lucid, critical, and authoritative reviews on current pharmacological topics.Articles, commissioned by the editor, follow specific author instructions.This journal maintains its scientific excellence and ranks among the top 10 most cited journals in pharmacology.
期刊最新文献
Pro-resolving lipid mediators and therapeutic innovations in resolution of inflammation. The pharmacodynamic and pharmacological mechanisms underlying nanovesicles of natural products: Developments and challenges. Exploring the landscape of post-translational modification in drug discovery. New drug discovery and development from natural products: Advances and strategies. Neurobiology of cancer: Adrenergic signaling and drug repurposing
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1